<DOC>
	<DOC>NCT02911636</DOC>
	<brief_summary>Stereotactic Ablative Radiation(SABR) 35 Gy in 5 fractions, once weekly to prostate with simultaneous intraprostatic boost to the MR detected nodule up to 50Gy + 25 Gy in 5 fractions, once weekly simultaneously to seminal vesicles (SV's) and pelvic lymph nodes + 6-18 months of ADT</brief_summary>
	<brief_title>5 Fractions of Pelvic SABR With Intra Prostatic SABR</brief_title>
	<detailed_description>SABR 25Gy / 5 fractions to pelvis; 35Gy / 5 fractions to prostate; up to 50Gy / 5 fractions to MR nodule</detailed_description>
	<criteria>Histologically confirmed prostate adenocarcinoma (centrally reviewed) High tier intermediate risk defined as: PSA 1020ng/ml AND (T2b2c OR Gleason 7 ) â€¢ Highrisk prostate cancer, defined as at least one of: T3, OR Gleason 810, OR PSA &gt; 20 ng/mL Willing to give informed consent to participate in this clinical trial Able and willing to complete Expanded Prostate Index Composite (EPIC) questionnaire Prior pelvic radiotherapy Contraindication to radical prostate radiotherapy e.g. connective tissue disease or inflammatory bowel disease Contraindication to prostate MRI Anticoagulation medication (if unsafe to discontinue for gold seed insertion) Diagnosis of bleeding diathesis Large prostate with significant arch interference on TRUS after 3 months of neoadjuvant ADT. Previous TURP Poor baseline urinary function defined as International Prostate Symptom Score (IPSS) &gt;20 Significant medical comorbidity rendering patient unsuitable for general anesthetic No evidence of castrate resistance (defined as PSA &lt; 3 ng/ml while testosterone is &lt; 0.7nmol/l. Patients could have been on combined androgen blockade but are excluded if this was started due to PSA progression. Definitive extrapelvic nodal or distant metastatic disease on staging investigations.</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>99 Years</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>